ATRS stock: buy or sell?

ATRS stock price: $3.30 -0.30% At close on August 22nd, 2019

Updated on:
August 22nd, 2019

2

Antares Pharma shares remained steady -0.30% to $3.30 today.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide.

Should I buy ATRS stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Antares Pharma stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ATRS will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Antares Pharma stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we detected 2 ratings published for ATRS stock in the last 30 days.

Is ATRS a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-3-4Raymond JamesStrong-BuyStrong-Buy
2019-2-25Cowenn/aOutperform

ATRS stock analysis

Daily outlook

Shares of Antares Pharma remained constant an unpleasant -0.30% and closed at $3.30.

Antares Pharma ended today at $3.30 and remained stable an unpleasant -0.30%. For the last 2 days when ATRS stock price broke up the SMA200d line, it gained $0.19 (6.11%). ATRS shows a short term strength with several rising tops and rising bottoms. In the very short term, on Friday it marked a new bottom at $3.07 that should act a support if Antares Pharma starts a trading flat base in the range of $3.07 - $3.38 Trading the long side, we should wait to a new breakout over $3.38 to find the next buy point.

ATRS stock chart (daily)

Weekly outlook

Antares Pharma shares boosted 5.10% this week, ending at $3.30. Early July ATRS plunged a frightening -12.25% in just one week. Early August ATRS skyrocketed a dazzling 6.73% in just one week.

Having descending tops is not good news for the long side. Although it's only a warning signal, investors should be on alert during next weeks to identify possible new signals. Loosing its previous bottom at would confirm the downtrend path. Early August ATRS price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

ATRS stock chart (weekly)

ATRS stock price history

ATRS IPO was on October 3rd, 1996 at $30.00 per share1. Since then, ATRS stock lost a -89.00%, with a yearly average of -4.00%.

1: Adjusted price after possible price splits or reverse-splits.

ATRS stock historical price chart

ATRS stock reached 52-week highs on March at $3.96, and all-time highs 1997-01-23 with a price of 31.88.

ATRS stock price target is $5.70

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' ATRS stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we only found 1 price prediction for Antares Pharma stock:
ATRS stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-3-4Raymond JamesRaises Target$5.25$5.657.6%
(in average)$5.30$5.708.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

Since February, when Antares Pharma presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
ATRS earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.03n/a
2017-Q2-n/a-0.02n/a
2017-Q3-n/a-0.03n/a
2017-Q42018-03-13-0.03-0.02n/a
2018-Q12018-05-08-0.03-0.04n/a
2018-Q22018-08-07-0.02-0.03n/a
2018-Q32018-11-06-0.02-0.01n/a
2018-Q42019-02-28-0.020.04n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Antares Pharma annual sales rocketed an extraordinary 16.58% to $63.55 million USD from $54.52 marked in 2017. When comparing 2018 vs 2017, similarly, profit margin (that is, the net income divided by revenues) climbed a 20.46% to -10.25%.

ATRS annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$21 M-$-20.51 M-99.5%-
2014$27 M28.52%$-35.15 M-132.6%71.39%
2015$46 M72.28%$-20.66 M-45.2%-41.23%
2016$52 M14.38%$-24.34 M-46.6%17.81%
2017$55 M4.39%$-16.74 M-30.7%-31.21%
2018$64 M16.58%$-6.52 M-10.3%-61.09%

Quarterly financial results

Antares Pharma reported $18.82 M in revenues for 2018-Q4, a 5.33% up compared to previous quarter. Reported quarter income marked $6.13 M with a profit margin of 32.59%. Profit margin climbed a 43.43% compared to previous quarter when profit margin was -10.84%. When comparing turnover to same quarter last year, Antares Pharma sales marked an outstanding increase and skyrocketed a 34.06%. Looking back to recent quarterly results, Antares Pharma posted 3 positive quarters in a row.
ATRS quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$12 M-$-4.74 M-39.5%-
2017-Q2$13 M11.74%$-2.84 M-21.2%-40.08%
2017-Q3$15 M12.16%$-5.45 M-36.2%91.99%
2017-Q4$14 M-6.73%$-3.72 M-26.5%-31.87%
2018-Q1$13 M-9.52%$-6.19 M-48.8%66.70%
2018-Q2$14 M11.49%$-4.52 M-31.9%-27.01%
2018-Q3$18 M26.17%$-1.94 M-10.8%-57.17%
2018-Q4$19 M5.33%$6.13 M32.6%-416.84%

Antares Pharma ownership

When you are planning to buy shares of a company, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Antares Pharma, 7.34% of all outstanding shares are owned by its staff.

In case of Antares Pharma stock, 42.29% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ATRS stock account 0.00%, no big difference from last month.

For a better understanding, the following table shows ownership data compared to other related companies:

ATRSANIPBDXJNJLLY
Market cap$536.6 M$807.5 M$68.8 B$349.9 B$121.7 B
Total shares162.6 M12.0 M269.7 M2,660.0 M1,090.0 M
Float shares140.2 M9.2 M269.1 M2,630.0 M796.0 M
  - Institutional holdings (%)42.3%81.5%87.5%69.2%81.5%
  - Insider holdings (%)7.3%11.4%0.3%0.1%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

ATRS summary

Thursday, August 22nd, 2019
Open$3.32
Close$3.30
Day range$3.27 - $3.37
Previous close$3.31
Session gain-0.30%
Average true range$0.13
50d mov avg$3.17
100d mov avg$3.01
200d mov avg$3.12
Daily patternlb03a
Weekly pattern lt01a

Antares Pharma performance

To better understand Antares Pharma performance you must compare its gains with other related stocks in same sector or industry. For Antares Pharma, the comparison is made against ANI Pharmaceuticals, Becton, Dickinson and, , Eli Lilly and, Mylan, Pfizer, Retractable Technologies, Teva Pharmaceutical Industries and West Pharmaceutical Services.
Stock3m6m12m
ATRSAntares Pharma12.63%2.48%-9.34%
ANIPANI Pharmaceutica...-2.04%11.12%17.03%
BDXBecton, Dickinson...8.85%2.86%1.17%
JNJ-5.27%-2.41%-0.66%
LLYEli Lilly and-3.90%-8.98%7.83%
MYLMylan0.32%-39.09%-50.79%
PFEPfizer-16.10%-17.35%-14.87%
RVPRetractable Techn...24.24%6.49%13.89%
TEVATeva Pharmaceutic...-33.21%-57.91%-68.46%
WSTWest Pharmaceutic...25.58%40.22%25.51%

Antares Pharma competitors

One check before trading any stock is to have a look a list of its competitors, in this case for Antares Pharma. We selected 9 companies as Antares Pharma competitors as they are in the same industry or have similar market objectives.